Hematuria News and Research

RSS

In medicine, hematuria, or haematuria, is the presence of red blood cells (erythrocytes) in the urine. It may be idiopathic and/or benign, or it can be a sign that there is a kidney stone or a tumor in the urinary tract (kidneys, ureters, urinary bladder, prostate, and urethra), ranging from trivial to lethal.

COVID-19 tied to elevated risk of benign prostatic hyperplasia complications

SARS-CoV-2 infection linked to increased benign prostatic hyperplasia (BPH) complications and medication use. Urological manifestations in COVID-19 patients emphasize the importance of awareness among clinicians.

22 Oct 2023

New diagnostic tool could revolutionize early bladder cancer detection

Bladder cancer has a five-year survival rate of over 80% when detected early, but this rate declines significantly as the disease progresses to advanced stages.

14 Aug 2023

Discovery of new biomarkers could lead to early detection of bladder cancer

A University of Houston biomedical engineer and his team are reporting the discovery of new biomarkers for early detection of bladder cancer (BC), among the most common cancers diagnosed in men in the U.S.

27 Apr 2023

How does SARS-CoV-2 affect the male genitourinary system?

In a recent paper published in the American Journal of Clinical and Experimental Urology, researchers reviewed existing data on the effects of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections on the male genitourinary (GU) tract.

7 Sep 2022

Understanding the impact of bladder cancer on daily life before and after diagnosis

In this interview, Dr. Ignacio Durán and Alex Filicevas, discuss key challenges and opportunities in the bladder cancer disease landscape and the future of care. They focus on the quality of life for patients and delve into the impact bladder cancer has on daily life, both before and after diagnosis and treatment, from the holistic perspective of both patients and HCPs.

From Janssen Pharmaceuticals 4 Jul 2022

Study shows glomerulonephritis after SARS-CoV-2 mRNA vaccination likely coincidental

In a recent study posted to the medRxiv* pre-print server, researchers assessed whether messenger ribonucleic acid (mRNA)-based coronavirus disease 2019 (COVID-19) vaccines increase the incidence of glomerulonephritis against the null hypothesis stating any observed temporal association between the two phenomena was purely coincidental.

26 May 2022

Assessing the association of COVID-19 and Immunoglobulin A vasculitis in children

In a recent study posted to the Research Square* preprint server, researchers conducted a systematic review to investigate any association between immunoglobulin A (IgA) vasculitis and coronavirus disease 2019 (COVID-19) in children.

8 Feb 2022

Study evaluates the potential benefits of mass dipstick screening to detect hematuria

As the saying goes, "the sooner the better," and such is the case for the detection of kidney and urological diseases. Early detection is key, and may be achieved through the use of a dipstick urine test.

4 Feb 2022

Urine sampling not to be restricted to children with unexplained fever, say researchers

In a systematic review, researchers assessed the diagnostic value of certain physical symptoms that children may display that could indicate a urinary tract infection.

17 Sep 2021

Immunomodulatory therapies for nephrological autoimmune diseases may help treat severe COVID-19

Various viruses and bacteria have long been known to cause autoimmune diseases where there is such a predisposition. This phenomenon also seems to play a major role in SARS-CoV-2, especially in severe courses.

8 Jun 2021

COVID-19 can cause long-term consequences for the kidneys

The kidneys are a target organ of COVID-19 and are affected very early in the course. However, this is precisely where there is strong prognostic potential: As early as last spring, COVID-19-associated nephritis was identified as an early warning signal for severe courses of the infectious disease and studies to that effect were published.

7 Jun 2021

UroCAD assay is better than urine cytology in detecting bladder cancer

Analysis of DNA copy number variants (CNVs) in the cells exfoliated in urine showed better sensitivity and similar specificity in detecting urothelial carcinoma compared with urine cytology.

9 Oct 2020

Indirect viral infection of the kidneys by SARS-CoV-2-induced inflammatory reaction

SARS-CoV-2-associated acute kidney injury is not uncommon. Many hospitalized COVID-19 patients - as many as 80% of critically ill COVID-19 patients, according to a current study - develop acute kidney injury, but without requiring dialysis in most cases. Proteinuria and hematuria are present in about half the cases.

8 Jun 2020

Kidney impairment significantly higher among hospitalized COVID-19 patients

Germany was not hit as hard by the SARS-CoV-2 pandemic as many other European countries. The reason for this is that the wave of infection reached Germany later, that the authorities were warned by the situation in Italy and Spain and at an early stage ordered a lockdown and conducted extensive testing.

5 Jun 2020

Treating hospitalized COVID-19 patients with anticoagulants may improve their survival chances

Treating hospitalized COVID-19 patients with anticoagulants-;blood thinners that slow down clotting-;may improve their chances of survival, researchers from the Mount Sinai COVID Informatics Center report.

7 May 2020

Innovative approach offers kidney-sparing treatment option for upper tract urothelial cancer

Treatment of low-grade upper tract urothelial cancer usually involves radical surgery to remove the kidney and ureter, highlighting the need for improved treatments.

30 Apr 2020

Merck presents MK-1454 Phase 1 data for treatment of advanced solid tumors or lymphomas

Merck, known as MSD outside the United States and Canada, today announced the first presentation of preliminary data from a Phase 1 clinical trial evaluating MK-1454, an investigational STING (stimulator of interferon genes) agonist, as monotherapy and in combination with KEYTRUDA (pembrolizumab), Merck's anti-PD-1 therapy, in patients with advanced solid tumors or lymphomas.

22 Oct 2018

Merck presents KEYNOTE-057 trial results for patients with high-risk non-muscle invasive bladder cancer

Merck, known as MSD outside the United States and Canada, today announced the first presentation of results from an interim analysis of KEYNOTE-057, a Phase 2 trial evaluating KEYTRUDA, Merck's anti-PD-1 therapy, for previously treated patients with high-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ or CIS plus papillary disease (Cohort A).

22 Oct 2018

NeoTract presents new clinical data from studies of UroLift System for patients with BPH

NeoTract, a wholly owned subsidiary of Teleflex Incorporated focused on addressing unmet needs in the field of urology, today announced the presentation of new clinical data at the World Congress of Endourology 2018 Annual Conference from two U.K. studies of the company's novel UroLift System for patients with Benign Prostatic Hyperplasia.

25 Sep 2018

CNDA approves KEYTRUDA for treatment of advanced melanoma

Merck, known as MSD outside the United States and Canada, today announced that KEYTRUDA, Merck's anti-PD-1 therapy, has been approved by the China National Drug Administration for the treatment of adult patients with unresectable or metastatic melanoma following failure of one prior line of therapy.

26 Jul 2018